Program
idursulfase beta
Also written as “Hunterase”.
Its studies are mostly in Mucopolysaccharidosis II · Sudden Infant Death, led by GC Biopharma.
Furthest: phase 3, since Jul 16, 20123 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GC Biopharma | 30 open or running | phase 3since Jul 16, 2012 | Jul 16, 2012 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2012First study: phase 3 study in Mucopolysaccharidosis IIFirst studyNCT01645189 · 6 enrolled · Korea, Republic of
- Jan 17, 2016Phase 2 study in Mucopolysaccharidosis IINCT02663024 · 20 enrolled
- Nov 17, 2025Phase 3 study in Sudden Infant DeathNCT07344376 · 30 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07344376Sudden Infant Death · South Korea | 3 | Completed | Dec 30, 2022 | 30 |
| NCT02663024Mucopolysaccharidosis II | 2 | UNKNOWN | Dec 2019 | 20 |
| NCT01645189Mucopolysaccharidosis II · Korea, Republic of | 3 | Completed | Sep 2013 | 6 |
How it is read
Names in the registry
- “Hunterase”, 2 entries
- “idursulfase beta”, 1 entry
Conditions, from the studies’ own filings
- Mucopolysaccharidosis II, 2 studies
- Sudden Infant Death, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.